Theravance Biopharma Inc Cash Flow-to-Debt Ratio
Theravance Biopharma Inc cash flow-to-debt ratio. Theravance Biopharma Inc (0TB) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of €-6.51 Million could theoretically repay 0% of its total liabilities (€182.78 Million) in one year. Check cash flow reinvestment rate of Theravance Biopharma Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Theravance Biopharma Inc (2014–2024)
Cash flow-to-debt ratio of Theravance Biopharma Inc from 2014 to 2024. Historical debt coverage capacity for Theravance Biopharma Inc across 11 annual periods. Check Theravance Biopharma Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Theravance Biopharma Inc Cash Flow-to-Debt Ratio by Year (2014–2024)
Theravance Biopharma Inc cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Theravance Biopharma Inc. For the full cash flow conversion analysis, see Theravance Biopharma Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.06x | €-11.54 Million | €178.62 Million | ▲ +59.6% |
| 2023 | -0.16x | €-27.00 Million | €169.00 Million | ▲ +85.9% |
| 2022 | -1.13x | €-186.99 Million | €165.60 Million | ▼ -287.5% |
| 2021 | -0.29x | €-207.86 Million | €713.39 Million | ▲ +10.1% |
| 2020 | -0.32x | €-250.40 Million | €772.81 Million | ▲ +13.9% |
| 2019 | -0.38x | €-238.20 Million | €632.67 Million | ▼ -104.1% |
| 2018 | -0.18x | €-112.87 Million | €611.82 Million | ▲ +70.1% |
| 2017 | -0.62x | €-201.05 Million | €326.22 Million | ▼ -79.9% |
| 2016 | -0.34x | €-98.99 Million | €289.02 Million | ▲ +88.4% |
| 2015 | -2.96x | €-168.86 Million | €57.05 Million | ▲ +18.9% |
| 2014 | -3.65x | €-175.16 Million | €47.98 Million | — |